Horizontal infection control measures: **Decolonization as Infection Prevention**

Loren G. Miller M.D., M.P.H. **Professor of Medicine** David Geffen School of Medicine at UCLA Chief, Division of Infectious Diseases Harbor-UCLA Medical Center

Topics to Be Discussed

• MDRO colonization in hospitals, SNFs

Consequences of MDRO colonization


Decolonization as prevention


Topics to Be Discussed

• MDRO colonization in hospitals, SNFs

Consequences of MDRO colonization

Decolonization as prevention






Leisner JJ. Front Microbiol 2020; 11:976.

Prevalence of

Carbapenem-Resistant Pathogens



https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance



Prevalence of Penicillin-Resistant S. aureus




Figure. Secular trends of approximate prevalence rates for penicillinase-producing, methicillin-susceptible strains of Staphylococcus aureus in hospitals (closed symbols) and the community (open symbols).

Chambers HF. *Emerg Infect Dis* 2001; 7:178-182

6 of the 18 most alarming antibiotic resistance threats cost the U.S. more than \$4.6 billion annually



Vancomycinresistant Enterococcus (VRE)

Carbapenemresistant Acinetobacter species (CRAsp)



Methicillinresistant Staphylococcus aureus (MRSA)

Carbapenemresistant Enterobacterales (CRE)



Extended-spectrum cephalosporin resistance in Enterobacterales suggestive of extendedspectrum β-lactamase (ESBL) production



www.cdc.gov/DrugResistance

Multidrugresistant (MDR) Pseudomonas aeruginosa



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Misuse of **ANTIBIOTICS** puts us all at risk.

Taking antibiotics when you don't need them speeds up antibiotic resistance. Antibiotic resistant infections are more complex and harder to treat. They can affect anyone, of any age, in any country.


Always seek the advice of a healthcare professional before taking antibiotics.





World Health Organization

Projected Antibiotic Consumption



MDRO Colonization/Contamination

- Growing number of MDROs (more than just MRSA!)
- Carriage associated with higher infection risk
- Carriers commonly shed MDROs
 - -HCW hands
 - -Objects



13

MDRO Colonization/Contamination

- Contamination of objects hard to remove
- Decolonization is time consuming

-screen, treat

 Need a broad solution, one that prevents transmission and reduces infections in carriers



14


MDRO Colonization in Hospitals

- MDRO colonization in hospitals is increasing
- 5 >20% of hospitalized patients have > 1 MDRO
- MDRO colonization in ICU > non-ICU
- Active surveillance for MDROs reveals many MRDOcolonized patient that were previously *not* identified

https://www.cdc.gov/infectioncontrol/guidelines/mdro/epidemiology.html Hachimi A et al. PAMJ-Clinical Med 2021; 5: 1 Kapsar T et al. BMC Antimicrob Resistance and Infect Control 2015; 4: 31




Prevalence of MDRO colonization in LTCFs




Rodriguez-Villodres A et al. Antibiotics 2021; 10: 680

"Iceberg" Effect of Colonization

- Survey of 28 SoCal NHs
- 48% of residents MDRO colonized lacksquare
 - 4% known to be MDRO colonized based on previous care/medical records
 - 44% detected only by active surveillance cultures





Topics to Be Discussed

• MDRO colonization in hospitals, SNFs

Consequences of MDRO colonization

Decolonization as prevention

MDRO Colonization and Infection Risk

- MRSA colonization in hospitalized pt's assd with ~30% MRSA *infection* risk
- VRE colonization a risk factor for VRE infection


-5 – 10 x increased risk compared to non-VRE colonized pt's

 ESBL colonization a risk factor for ESBL infection -OR = 9.6 [95% CI 2.9 - 33.3


> Milstone AM A et al. Clin Infect Dis 2011; 53: 853-59 Amberpet R et al. J Lab Physicians 2018; 10:89-94 Massart N et al. Eur J Clin Microbiol Infect Dis 202; 29: 889-95



Post-Discharge MRSA Infection Risks



Dantes R et al. *JAMA Int Med* 2013; 173: 1970-78



Source Control

- Numerous resistant pathogens
- Shedding is common and persistent
- Contamination hard to remove
- Need a broad, simple solution
- Impact carriers not just prevent new carriers

Topics to Be Discussed

• MDRO colonization in hospitals, SNFs

Consequences of MDRO colonization


Decolonization as prevention

Patient Instructions: Staphylococcus aureus Decolonization

Please follow the instructions below to decolonize for Staphylococcus aureus.

Nasal Ointment – Bactroban (Mupirocin 2%)

- 1. You will be provided with prescription for Bactroban or may be provided with a tube of the nasal ointment.
- Use enough ointment to coat the inside of the nostril every time you apply the ointment.
- 3. Put ointment on the tip a cotton swab.
- 4. Apply ointment to inside of one nostril.
- 5. Gently press nostril together and release several times (for about a minute) to spread the ointment in the nostril.
- 6. Repeat process in the other nostril using the other end of the cotton swab or a new swab.





Advantages of Decolonization

- Broad vs targeted intervention
- Obviates screening
- Embedded in routine bathing activities
- Reduces shedding
- Reduces contamination
- Reduces transmission
- Reduces infection

Prevention of Colonization and Infection by Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae in Long-term Acute-Care Hospitals

Mary K. Hayden,^{1,2} Michael Y. Lin,¹ Karen Lolans,² Shayna Weiner,¹ Donald Blom,¹ Nicholas M. Moore,³ Louis Fogg,⁴ David Henry,⁵ Rosie Lyles,⁶ Caroline Thurlow,¹ Monica Sikka,¹ David Hines,⁷ and Robert A. Weinstein^{1,6}; for the Centers for **Disease Control and Prevention Epicenters Program**

50% decline in acquisition 56% decline in bacteremia

Hayden MK. Clin Infect Dis 2015 Apr 15;60(8):1153-61.



What is Decolonization?

- Use of topical antiseptics to reduce the bacterial bioburden on the body to prevent carriage and infection
- Commonly
 - Chlorhexidine (CHG) for skin and wound bathing
 - Mupirocin or iodophor for nasal use
- Used in vulnerable times, high risk populations
- Active against MDROs
- CHG and iodophor used in healthcare for 60+ years
- Strong safety record



Chlorhexidine Guidance

- Dental gingivitis, periodontal disease
- Central line skin prep
- Surgical skin prep
- Surgical pre-operative bathing
- Wound cleanser
- ICU bathing to reduce microbial burden and infection



ICU Decolonization Evidence Summary

Author	Study Year	Study Type	Hospital	ICU	Ν	Findings	Publicat
Vernon	10/02-12/03	Observational	1	1	1,787	65% less VRE acquisition 40-70% less VRE on skin, HCW hands, environment	Arch Intern M 166:306-312
Climo	12/04-1/06	Observational	4	6	5,293	66% less VRE BSI 32% less MRSA acquisition 50% less VRE acquisition	Crit Care Med 37:1858–1865
Bleasdale	12/05-6/06	Observational	1	2	836	61% less primary BSI	Arch Intern M 167(19):2073-:
Popovich	9/04-10/06	Observational	1	1	3,816	87% less CLABSI 41% less blood contaminants	ICHE 2009; 30(10):959-63
Climo	8/07-2/09	Cluster RCT	6	9	7,727	23% less MRSA/VRE acquisition	N Engl J Med 2 368:533-42
Milstone	2/08-9/10	Cluster RCT	5	10	4,947	36% less total BSI <mark>(</mark> as treated)	Lancet. 2013; 381(9872):109
Huang	1/09-9/11	Cluster RCT	43	74	122,646	37% less MRSA clinical cultures 44% less all-cause BSI	N Engl J Med 368:2255-2265



ation

Med 2006;

- d 2009;
- 5
- Med 2007;
- 3-2079

2013;

99-106

d 2013 55

Preceding Decolonization Trials

REDUCE MRSA ICU Trial¹

- > 43 hospital cluster randomized trial, 75,000 patients
- > Universal decolonization with chlorhexidine (CHG) baths and nasal mupirocin \rightarrow 44% lower bacteremia, 37% lower MRSA

ABATE Infection Trial²

- > 53 hospital cluster randomized trial, 339,000 patients
- \succ In patients with medical devices, 37% reduction in MRSA and VRE, 32% reduction in all-cause bloodstream infection

CLEAR Trial ³

- > Individual RCT of 2,121 recently hospitalized MRSA carriers
- > Serial decolonization led to 30% reduction in MRSA infection
- > NNT ~30 to avoid one infection or hospitalization

¹ Huang S et al. N Engl J Med 2013:368:2255-2265

² Huang S et al. Lancet 2019;393(10177):1205-1215

³ Huang S et al. N Engl J Med 2019: 380(7):638-50

ORIGINAL ARTICLE

Decolonization in Nursing Homes to Prevent Infection and Hospitalization

L.G. Miller, J.A. McKinnell, R.D. Singh, G.M. Gussin, K. Kleinman, R. Saavedra, J. Mendez, T.D. Catuna, J. Felix, J. Chang, L. Heim, R. Franco, T. Tjoa, N.D. Stone, K. Steinberg, N. Beecham, J. Montgomery, D.A. Walters, S. Park, S. Tam, S.K. Gohil, P.A. Robinson, M. Estevez, B. Lewis, J.A. Shimabukuro, G. Tchakalian, A. Miner, C. Torres, K.D. Evans, C.E. Bittencourt, J. He, E. Lee, C. Nedelcu, J. Lu, S. Agrawal, S.G. Sturdevant, E. Peterson, and S.S. Huang

ABSTRACT

BACKGROUND

Nursing home residents are at high risk for infection, hospitalization, and colonization with multidrug-resistant organisms.

METHODS

We performed a cluster-randomized trial of universal decolonization as compared with routine-care bathing in nursing homes. The trial included an 18-month baseline period and an 18-month intervention period. Decolonization entailed the use of chlorhexidine for all routine bathing and showering and administration of nasal povidone-iodine twice daily for the first 5 days after admission and then twice daily for 5 days every other week. The primary outcome was transfer to a hospital due to infection. The secondary outcome was transfer to a hospital for any reason.

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Dr. Miller can be contacted at lgmiller@ucla.edu or at the Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, 1124 W. Carson St., Box 466, Torrance, CA 90509.

This article was published on October 10, 2023, at NEJM.org.

N Engl J Med 2023;389:1766-77.





The PROTECT Trial:

A Cluster Randomized Clinical Trial of Decolonization of Nursing Homes Residents to Prevent Infection and Hospitalization: Focus on Microbiologic Outcomes

Loren G. Miller MD MPH Lundquist Institute at Harbor-UCLA Medical Center, Torrance CA for the PROTECT Trial Team



Decolonization Trials

- Targeted Prevention
 - \blacktriangleright Recurrent *S. aureus* infection¹
 - \blacktriangleright Pre-operative *S. aureus* carriers ²⁻³
- Universal Prevention
 - ➢ ICU ⁴⁻⁶
 - ➢ Non-ICU⁷
 - Post-discharge⁸

¹Liu C CID 2011;52:285-92 (IDSA Guideline) ² Bode LGM NEJM 2010;362:9-17 ³Perl T NEJM 2002;346:1871-7 ⁴Climo M NEJM 2013;368:533-42

⁵ Milstone A Lancet 2013;381:1099-106 ⁶ Huang SS et al. NEJM 2013;368:2255-65 ⁷ Huang SS et al. Lancet 2019;393(10177):1205-15 ⁸Huang SS et al. NEJM 2019;380(7):638-50

Need to Prevent Nursing Home Infections

- 3 million healthcare-associated infections (HAIs) estimated to occur in nursing homes (NHs) annually in U.S.
- Each year, U.S. NH HAIs associated with:
 - ► 150,000 hospital admissions
 - **≻**380,000 deaths

https://health.gov/sites/default/files/2019-09/hai-action-plan-ltcf.pdf Strausbaugh LJ, Joseph CL. ICHE 2000; 21(10):674-9. Magaziner J et al. JAGS. 1991; 39(11):1071-8. Heudorf U et al. Euro Surveill. 2012; 17(35). McKinnell JA et al. CID 2019; 69(9):1566-73.



Need to Prevent Nursing Home Infections

- NHs care for the highly vulnerable:
 - elderly age
 - high risk comorbid conditions
 - high multidrug-resistant organism (MDRO) prevalence
 - MRSA, VRE, ESBL producing gram-negatives, CRE
 - limited self hygiene
- 65% of nursing home residents harbor an MDRO

Strausbaugh LJ, Joseph CL. ICHE 2000; 21(10):674-9. Magaziner J et al. JAGS. 1991; 39(11):1071-8. Heudorf U et al. Euro Surveill. 2012; 17(35). McKinnell JA et al. CID 2019; 69(9):1566-73.



The PROTECT Trial

Trial Design

- 28 nursing home cluster randomized trial
- Orange County and Los Angeles County nursing homes
- 18-month baseline, 18-month intervention period \bullet


Arm 1: Routine Care

Usual practice for showering/bathing \bullet

Arm 2: Decolonization

- CHG bathing for all residents (on admit, then per routine) \bullet
- Nasal iodophor x 5d bid, facility-wide every other week

https://clinicaltrials.gov/ct2/show/NCT03118232 Funded: AHRQ



Intervention: Replacing Soap with CHG

- Liquid CHG for showering
 - 4% rinse off CHG
- CHG cloths for bed bathing
 - 2% leave on CHG





2% cloths for bath




Intervention: Nasal Decolonization

- 10% povidone-iodine swabs (iodophor) to each nostril
- Twice daily for entire facility
- On admission and M-F every other week






Implementation Aids



отест	-
s showers	
r week irector	

Baseline and Intervention Periods



Allows a "difference in differences" evaluation where intervention data from each participating NH is compared to its own baseline period, and those changes are compared across study groups. This helps account for unmeasured or imbalanced confounders



Outcomes: Publicly Reported Data

Primary Outcome

• Hospital transfers due to infection (% of discharges to a hospital due to infection)

Secondary Outcome

All hospital transfers (% of discharges to a hospital)


Additional Outcomes (secondary manuscripts)

- MDRO prevalence (MRSA, VRE, ESBL, CRE)¹
- Outcomes stratified by long vs short stay residents
- Emergency department visits due to infection




Analysis


- Main results are as-randomized, unadjusted
- Difference in differences approach \bullet
 - Compared baseline to intervention period within facility and then compared aggregated results across arms
 - \succ Generalized linear mixed models assessing the difference in differences of each outcome using an arm by period interaction term and clustering by NH
- Two outcomes \bullet
 - Significance level set at 0.025 due to multiple comparisons
 - > Powered for 15% difference in infection, 8% difference in hospitalization



Characteristics of PROTECT Facilities

Variable	Decolonization Arm	Routine Ar
	Median (Range)	
Number of Facilities	14	14
Mean Age	76.6 (72, 79)	75.6 (71, 8
% Male	42 (38, 47)	44 (37, 53
Mean Licensed Beds	99 (59 <i>,</i> 195)	99 (69 <i>,</i> 299
Average Daily Census	104 (57, 215)	101 (71, 23
Length of Stay	205 (185, 298)	219 (203, 25
Elixhauser Comorbidity Score	3.6 (2.8, 4.7)	3.6 (3.0, 4.
% Diabetes	37 (30, 41)	41 (34, 46
% Chronic Lung Disease	23 (18, 33)	22 (19, 25
% Renal Failure	20 (15, 24)	20 (18, 25








% Hospital Transfers Due to Infection





Intervention vs Baseline (RR) Routine Care = 1.00 (95% CI 0.96-1.04)


Difference in Differences: 16.6% (95% CI: 11.0% to 21.8%, P<0.001)

Miller LG et al. New Engl J Med 2023; 389:1766-77



Decolonization = 0.83 (95% CI 0.79-0.88)


Secondary Outcome: % of Discharges to a Hospital, by Group





Transfer to a Hospital for Any Reason

Transfer to a Hospital for Any Reason В



Intervention vs Baseline (RR) Routine Care = 1.08 (95% CI 1.04-1.12)

Difference in Differences: 14.6% (95% CI: 9.7% to 19.2%, P<0.01)


Miller LG et al. New Engl J Med 2023; 389:1766-77




Decolonization = 0.92 (95% CI 0.88-0.96)

Intervention: CHG & Iodophor Compliance

CHG



Iodophor









Conclusions

- Universal nursing home resident decolonization with CHG for routine bathing and showering
 - 17% Reduction in % of hospitalizations due to infection
 - 15% Reduction in % of discharges to a hospital
- NNTs = 9.7, 8.9 (as treated 6.8 and 5.8)

Conclusions (2)

- Mechanistically, \downarrow in clinical infections likely related to \downarrow in **MDRO** colonization
- CHG \downarrow skin bacterial bioburden > > soap & water
- Iodophor \downarrow MRSA nasal colonization

So

- What about adding CHG to mupirocin in HD patients?
 - Mupirocin mono-Rx antiquated
 - Data from other populations suggest \downarrow infection rate
- Challenges to HD patients do CHG bathing?
- Does decolonization reduce non-*S. aureus* infections? lacksquare
- Other...